Skip Navigation


Annals of Oncology Advance Access originally published online on March 8, 2006
Annals of Oncology 2006 17(6):920-927; doi:10.1093/annonc/mdl039
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/6/920    most recent
mdl039v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ganti, A. K.
Right arrow Articles by Armitage, J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ganti, A. K.
Right arrow Articles by Armitage, J. O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience

A. K. Ganti1,4,*, D. D. Weisenburger2, L. M. Smith3, C. P. Hans2, R. G. Bociek1, P. J. Bierman1, J. M. Vose1 and J. O. Armitage1

1 Department of Internal Medicine, Division of Oncology/Hematology, 2 Department of Pathology and Microbiology and 3 Department of Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE; 4 Department of Internal Medicine, Omaha VA Medical Center, Omaha, NE, USA

* Correspondence to: A. K. Ganti, Department of Internal Medicine, 987680 Nebraska Medical Center, Omaha, NE 68198-7680, USA. Tel: +1-402-559-5520; Fax: +1-402-559-6520; E-mail: aganti{at}unmc.edu

Background: The aim of the study was to determine the outcome and clinical features predictive of survival in patients with follicular lymphoma (FL) treated aggressively and to determine the rate of disease-specific mortality in patients with grade 3 FL (FL3).

Materials and methods: Four hundred and twenty-one patients with FL who were treated with various anthracycline-based chemotherapy regimens were included in this retrospective study.

Results: Patients with FL3 and a diffuse component of >50% had the worst outcome, with a hazard ratio of dying of 2.2 (95% CI 1.4–3.4) compared with patients with FL1 or FL2, and a ratio of 1.6 (95% CI 1.02–2.5) compared with FL3 with a diffuse component of ≤50% by multivariate analysis (P = 0.0026). Patients with FL3a had an outcome similar to those with FL3b. In patients with FL3 and a diffuse component of ≤50%, the overall and event-free survival curves showed a plateau for patients younger than 60 years of age. However, there were no differences in the cumulative incidence of relapse/progression or lymphoma-specific/treatment-related mortality between the two age groups.

Conclusions: Less than half of the patients with FL3 and a diffuse component of ≤50% treated with anthracycline-based combination chemotherapy will relapse and relapses are uncommon after 6 years. Older patients should be offered the same aggressive chemotherapy as younger patients.

Key words: age, anthracyclines, grade 3 follicular lymphoma, outcomes, therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. W. Friedberg, M. D. Taylor, J. R. Cerhan, C. R. Flowers, H. Dillon, C. M. Farber, E. S. Rogers, J. D. Hainsworth, E. K. Wong, J. M. Vose, et al.
Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
J. Clin. Oncol., March 10, 2009; 27(8): 1202 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. A. McCormick, S. Reddy, S. J. Reinl, T. I. Cameron, D. K. Czerwinkski, F. Vojdani, K. M. Hanley, S. J. Garger, E. L. White, J. Novak, et al.
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study
PNAS, July 22, 2008; 105(29): 10131 - 10136.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
P. P. Piccaluga, A. Califano, U. Klein, C. Agostinelli, B. Bellosillo, E. Gimeno, S. Serrano, F. Sole, Y. Zang, B. Falini, et al.
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
Haematologica, July 1, 2008; 93(7): 1033 - 1038.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. J. Overman, L. Feng, B. Pro, P. McLaughlin, M. Hess, F. Samaniego, A. Younes, J. E. Romaguera, F. B. Hagemeister, L. Kwak, et al.
The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma
Ann. Onc., March 1, 2008; 19(3): 553 - 559.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S. Prakash and S. H Swerdlow
Nodal aggressive B-cell lymphomas: a diagnostic approach
J. Clin. Pathol., October 1, 2007; 60(10): 1076 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology, January 1, 2007; 2007(1): 216 - 225.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
L. H. Sehn
Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma
Hematology, January 1, 2006; 2006(1): 295 - 302.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.